Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HypoSens

Financiado

Cerrado

Nano confined photonic system for detection of breast cancer spread to the lymph...

Nano confined photonic system for detection of breast cancer spread to the lymph nodes The Vision of HypoSens is to develop a widely accepted,non-invasive and crucial prognostic tool for breast cancer progression in early stages to help clinicians and specially oncologists to decide about prompt therapy approaches t... ver más

31/10/2019

LEITAT

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ACONDICIONAMIENTO TARRASENSE - LEITAT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 51M€

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-10-31

ICT-29-2016: Photonics KET 2016

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

LEITAT

672.08K€ | Lider

METALURGICA MARINA

794.23K€ | Participante

MPG

490.98K€ | Participante

TECNOLOGIAS AVANZADAS INSPIR...

83.55K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DIAG-CANCER Diagnosis Screening and Monitoring of Cancer Diseases via E... 1M€ Cerrado

RBCE-GENODIAGNOSENS Recuring breast cancer early genetic diagnostic on a chip 159K€ Cerrado

CanSENS Colon Cancer Breath Screening using Nanowire SERS 146K€ Cerrado

MAT2017-84959-C2-1-R BIOSENSOR BASADO EN NANOPARTICULAS SUPERPARAMAGNETICAS PARA... 121K€ Cerrado

SERENA Development of an electrochemical multiSEnsor platform for t... 161K€ Cerrado

NanoNIR Development of a fluorescence based nanotool for early breas... 181K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2016-10-26
Fecha Fin: 2019-10-31

Líder del proyecto

ACONDICIONAMIENTO TARRASENSE - LEITAT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 51M€

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The Vision of HypoSens is to develop a widely accepted,non-invasive and crucial prognostic tool for breast cancer progression in early stages to help clinicians and specially oncologists to decide about prompt therapy approaches to patients and improve quality of life and expectancy. Our breakthrough research will focus on the development, pre-clinical and clinical validation, and industrial demonstration of a unique all optical cancer prognostic system that will determine presence of cancer cells in the breast lymph nodes and characterize them, which correlates with presence of metastasis and bad prognosis. HypoSens prognostic system will consist of a non-invasive Near-infrared imaging device able to register signals through scattering media enabled by the implementation of wavefront shaping,that will process data collected by injected tumour-targeted body antibody functionalised nano-particles containing porphyrin sensors that will determine local oxygen concentration and local temperature distribution in the cancer cells.The HypoSens imaging system is strategically designed to offer a non-invasive alternative to the Sentinel Lymph Node Biopsy,the current surgical procedure for breast cancer staging. With an approximate cost of 60,000€ per device unit and additional 5,000€ per patient, the device is an affordable, accurate, easy to use prognostic solution for clinicians towards more accurate and fast diagnostics and personalised treatment options.The initial target of the project is metastatic breast cancer, with potential later involvement in other cancer markets, e.g. vulval, renal, colorectal, gastric etc (via the use of different tumor-targeting moiety).With an estimated 1.7 million new cases each year, breast cancer is the most common cancer among women worldwide.Its low cost will enable a wide and fast take-up by clinicians and hospitals leading to an important reduction of the economic and societal burden related to the diagnosis and treatment of cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores